FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308447204> ?p ?o ?g. }

• W4308447204 endingPage "5449" @default.
• W4308447204 startingPage "5449" @default.
• W4308447204 abstract "BRAF V600E mutation drives uncontrolled cell growth in most melanomas. While BRAF V600E tumors are initially responsive to BRAF inhibitors, prolonged treatment results in inhibitor resistance and tumor regrowth. Clinical data have linked the NRAS Q61K, KRAS G13D and MEK1 Q56P mutations to the BRAF inhibitor resistance. However, development of novel therapeutics is hindered by the lack of relevant isogeneic cell models. We employed CRISPR/Cas9 genome engineering to introduce NRAS Q61K, KRAS G13D and MEK1 Q56P mutations into the A375 melanoma cell line with endogenously high expression of BRAF V600E. The resulting isogenic cell lines are resistant to BRAF inhibitors. The A375 MEK1 Q56P isogenic cells are additionally resistant to MEK inhibitors as single agent, but interestingly, these cells become sensitive to MEK/BRAF inhibitor combo. Our results suggest that resistance in the NRAS and MEK isogenic lines is driven by constitutive MEK/ERK signaling, while the resistance in the KRAS isogenic line is driven by EGFR overexpression. Interestingly, the KRAS G13D isogenic line displays elevated PD-L1 expression suggesting the KRAS G13D mutation could be a potential indication for immunotherapy. Overall, these three novel isogenic cell models with endogenous level RAS and MEK1 point mutations provide direct bio-functional evidence demonstrating that acquiring a drug-resistant gene drives tumor cell survival and may simultaneously introduce new indications for combo therapy or immunotherapy in the clinic." @default.
• W4308447204 created "2022-11-12" @default.
• W4308447204 creator A5011419674 @default.
• W4308447204 creator A5019744308 @default.
• W4308447204 creator A5063675060 @default.
• W4308447204 creator A5083697699 @default.
• W4308447204 creator A5088001760 @default.
• W4308447204 date "2022-11-05" @default.
• W4308447204 modified "2023-09-25" @default.
• W4308447204 title "CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy" @default.
• W4308447204 cites W1981602821 @default.
• W4308447204 cites W1985821753 @default.
• W4308447204 cites W2003402062 @default.
• W4308447204 cites W2009642188 @default.
• W4308447204 cites W2032211985 @default.
• W4308447204 cites W2040622041 @default.
• W4308447204 cites W2041255253 @default.
• W4308447204 cites W2047942701 @default.
• W4308447204 cites W2062109911 @default.
• W4308447204 cites W2080686146 @default.
• W4308447204 cites W2100370559 @default.
• W4308447204 cites W2105017561 @default.
• W4308447204 cites W2105660237 @default.
• W4308447204 cites W2106543129 @default.
• W4308447204 cites W2114903025 @default.
• W4308447204 cites W2116386978 @default.
• W4308447204 cites W2128542677 @default.
• W4308447204 cites W2138619415 @default.
• W4308447204 cites W2147592245 @default.
• W4308447204 cites W2149672704 @default.
• W4308447204 cites W2163188200 @default.
• W4308447204 cites W2163655212 @default.
• W4308447204 cites W2166262263 @default.
• W4308447204 cites W2168143310 @default.
• W4308447204 cites W2170588458 @default.
• W4308447204 cites W2171367970 @default.
• W4308447204 cites W2251851976 @default.
• W4308447204 cites W2331628193 @default.
• W4308447204 cites W2511665693 @default.
• W4308447204 cites W2590493137 @default.
• W4308447204 cites W2601596971 @default.
• W4308447204 cites W2604121843 @default.
• W4308447204 cites W2745149102 @default.
• W4308447204 cites W2886704243 @default.
• W4308447204 doi "https://doi.org/10.3390/cancers14215449" @default.
• W4308447204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36358868" @default.
• W4308447204 hasPublicationYear "2022" @default.
• W4308447204 type Work @default.
• W4308447204 citedByCount "2" @default.
• W4308447204 countsByYear W43084472042023 @default.
• W4308447204 crossrefType "journal-article" @default.
• W4308447204 hasAuthorship W4308447204A5011419674 @default.
• W4308447204 hasAuthorship W4308447204A5019744308 @default.
• W4308447204 hasAuthorship W4308447204A5063675060 @default.
• W4308447204 hasAuthorship W4308447204A5083697699 @default.
• W4308447204 hasAuthorship W4308447204A5088001760 @default.
• W4308447204 hasBestOaLocation W43084472041 @default.
• W4308447204 hasConcept C104317684 @default.
• W4308447204 hasConcept C121608353 @default.
• W4308447204 hasConcept C184235292 @default.
• W4308447204 hasConcept C21790070 @default.
• W4308447204 hasConcept C2776131300 @default.
• W4308447204 hasConcept C2776470698 @default.
• W4308447204 hasConcept C2777658100 @default.
• W4308447204 hasConcept C2777701055 @default.
• W4308447204 hasConcept C2778472372 @default.
• W4308447204 hasConcept C2781187634 @default.
• W4308447204 hasConcept C2781249067 @default.
• W4308447204 hasConcept C2994587330 @default.
• W4308447204 hasConcept C501734568 @default.
• W4308447204 hasConcept C502942594 @default.
• W4308447204 hasConcept C54355233 @default.
• W4308447204 hasConcept C57074206 @default.
• W4308447204 hasConcept C81885089 @default.
• W4308447204 hasConcept C86803240 @default.
• W4308447204 hasConcept C98108389 @default.
• W4308447204 hasConceptScore W4308447204C104317684 @default.
• W4308447204 hasConceptScore W4308447204C121608353 @default.
• W4308447204 hasConceptScore W4308447204C184235292 @default.
• W4308447204 hasConceptScore W4308447204C21790070 @default.
• W4308447204 hasConceptScore W4308447204C2776131300 @default.
• W4308447204 hasConceptScore W4308447204C2776470698 @default.
• W4308447204 hasConceptScore W4308447204C2777658100 @default.
• W4308447204 hasConceptScore W4308447204C2777701055 @default.
• W4308447204 hasConceptScore W4308447204C2778472372 @default.
• W4308447204 hasConceptScore W4308447204C2781187634 @default.
• W4308447204 hasConceptScore W4308447204C2781249067 @default.
• W4308447204 hasConceptScore W4308447204C2994587330 @default.
• W4308447204 hasConceptScore W4308447204C501734568 @default.
• W4308447204 hasConceptScore W4308447204C502942594 @default.
• W4308447204 hasConceptScore W4308447204C54355233 @default.
• W4308447204 hasConceptScore W4308447204C57074206 @default.
• W4308447204 hasConceptScore W4308447204C81885089 @default.
• W4308447204 hasConceptScore W4308447204C86803240 @default.
• W4308447204 hasConceptScore W4308447204C98108389 @default.
• W4308447204 hasIssue "21" @default.
• W4308447204 hasLocation W43084472041 @default.
• W4308447204 hasLocation W43084472042 @default.

• next